Tapinarof (pediatric plaque psoriasis) is an Organon & Co. program.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Sponsor: Organon & Co. (OGN). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
No upcoming catalyst is on our calendar for Tapinarof (pediatric plaque psoriasis); no FDA decisions are on record below.
No FDA decision for Tapinarof (pediatric plaque psoriasis) is in our archive yet.
Organon & Co. (OGN).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.